Zimmer Biomet Holdings (ZBH) Tops Q1 EPS by 18c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus

May 4, 2021 6:35 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Zimmer Biomet Holdings (NYSE: ZBH) reported Q1 EPS of $1.71, $0.18 better than the analyst estimate of $1.53. Revenue for the quarter came in at $1.85 billion versus the consensus estimate of $1.76 billion.

"Our performance was stronger than we anticipated in the first quarter, as we saw signs of the pandemic beginning to subside across many regions toward the end of the quarter driven by acceleration of vaccine rollout. As we move into the second quarter, we expect that momentum to continue and believe we are well-positioned to meet the needs of our customers as elective procedures return," said Bryan Hanson, President and CEO of Zimmer Biomet. "Despite the challenges of COVID-19, the transformation of our business has continued over the past year. We are proud of the milestones Zimmer Biomet has already accomplished in 2021 and we have confidence that we can drive significant value for our key stakeholders as we move our Mission forward."


Zimmer Biomet Holdings sees FY2021 EPS of $7.60-$8.00, versus the consensus of $7.72.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Guidance, Hot Guidance, Management Comments

Related Entities